Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Summary

This phase II trial studies how well pembrolizumab and HER2Bi-armed activated T cells work in treating patients with castration resistant prostate cancer that has spread to other places in the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. HER2Bi-armed activated T cells are made using T cells and may target and kill cancer cells. Giving pembrolizumab and HER2Bi-armed activated T cells may work better in treating patients with castration resistant prostate cancer.

Timeline

Start

2018-06-07

Primary completion

2021-01-20

Completion

2022-11-07

Publications

• Vaishampayan UN, Heilbrun L, Vaishampayan N, Harper FWK, Shi D, Smith D, Green K, Guru K, Li Q, Kuettel M, Chatta G, Maier J, Dickow B, Moore TF, George S. Phase II Trial of Concurrent Nivolumab and Radiation Therapy for Muscle-Invasive Bladder Cancer of Older or Chemotherapy-Ineligible Patients. Int J Radiat Oncol Biol Phys. 2024 Apr 1;118(5):1472-1480. doi: 10.1016/j.ijrobp.2023.11.024. Epub 2023 Nov 18.

Drugs

Indications